The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...
Poly(ADP-ribose) polymerase (PARP) inhibitors should be considered a treatment option for patients with uterine leiomyosarcomas harboring BRCA2 deep deletions, researchers advised. PARP inhibitors are ...
SAN DIEGO – Saruparib, a selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), demonstrated a promising objective response rate and progression-free survival in patients with certain homologous ...
Olaparib is the only PARP inhibitor that significantly improves overall survival in PSROC, distinguishing it from other PARP inhibitors. All four PARP inhibitors enhance progression-free survival, ...
Niraparib approved for all-comers whose tumors responded to chemotherapy Platinum response serves as a clinical biomarker indicating potential DNA repair deficiency. The FDA restricted ...
A group of familiar faces to Incyte watchers has broken off to start their own biotech, pulling in $102 million to develop competitors to approved cancer drugs from AstraZeneca, GSK, Novartis and ...
The University of Texas MD Anderson Cancer Center’s Timothy Yap, M.D., doesn’t know why AstraZeneca’s PARP inhibitor saruparib seems to be spurring responses in patients who have previously not had ...
Among patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations, nearly half (48.8%) did not receive a PARP inhibitor, despite recent FDA approvals and recent trials ...
AstraZeneca and Merck & Co. were the first to grab an FDA approval for their PARP inhibitor Lynparza, and, despite growing competition, the drug is set to remain top dog in the PARP space. That’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback